Cellectar Biosciences, Inc. entered into agreements on June 5, 2025, for the immediate exercise of warrants to purchase a total of 8,301,322 shares of common stock at a reduced price of $0.3041 each, which were originally issued in 2020, 2022, and 2024. This transaction is expected to close on June 6, 2025, subject to customary conditions.